[3]Phillip J. Mease, et al. Efficacy and safety of deucravacitinib in patients with active psoriatic arthritis who are naive to biologic disease-modifying antirheumatic drugs or have previously received TNF inhibitor treatment: week 1...
2.https://www.sciencedirect.com/science/article/pii/S2352396423004061 3.https://news.bms.com/news/details/2022/U.S.-Food-and-Drug-Administration-Approves-Sotyktu-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis/default.aspx 4.https://www.takeda.com/newsroom/ne...
psoriasis domain5,6.#Updated EULAR treatment recommendations for psoriatic arthritis (PsA) include newly approved medications, recognize the need for treatment tailored to the individual and encourage targets of remission or low disease activity2.#Guselkumab, the first of a new class of drugs that ...
The European Commission has approvedbimekizumab(Bimzelx) for the treatment of activepsoriatic arthritis(PsA) and active axial spondylarthritis (axSpA) in adults. The IL-17A and IL-17F inhibitor has already been approved for the treatment of moderate to severeplaque psoriasisin the European Union...
Guselkumab (Tremfya) received Food and Drug Administration approval for the treatment of psoriatic arthritis (PsA) almost 2 years ago on the basis of a phase 3 trial, but a new substudy from that trial has now demonstrated long-term benefit in the subgroup of patients who entered the trial ...
Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate response or intolerance to at least one biologic disease-modifying antirheumatic drug (DMARD). Methods In this 24-week rand...
Prior to this, her psoriasis was managed for 15 years with varying results with numerous topical treatments and phototherapy as well as several courses of cyclosporine. At one point, she was prescribed a phosphodiesterase-4 (PDE-4) inhibitor but had to discontinue treatment after 12 weeks owing ...
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well. †RINVOQ is not approved to treat plaque psoriasis. My swelling went down.And my hands became less red. Discover how real patients like Anna became inspired to take on PsA...
Sheetal Desai, MD, leads the discussion on the recent approval of guselkumab, an IL-23 inhibitor, for the treatment of adults with active psoriatic arthritis. EP.1:Overview of Psoriatic Arthritis (PsA) EP.2:Impact of PsA on Quality of Life ...
RINVOQ is a JAK inhibitor for adults with active psoriatic arthritis (PsA) in whom TNF blockers did not work well. †RINVOQ is not approved to treat plaque psoriasis. My swelling went down.And my hands became less red. Discover how real patients like Anna became inspired to take on PsA...